Cannabis firm Organigram's Q3 revenue beats estimates

Organigram Global

13/08/2025 11:09

Overview

Organigram fiscal Q3 net rev rises 72% yr/yr, beating analyst expectations

Adjusted EBITDA for fiscal Q3 grows 64% yr/yr, driven by higher revenue

Company expands U.S. presence, generating revenue and increasing exports

Outlook

Organigram expects adjusted gross margin to improve with Motif synergies

Company anticipates sustained profitability and free cash flow in near-term

Company aims to expand product portfolio and international presence

Result Drivers

MOTIF ACQUISITION - Co attributes revenue growth to contributions from Motif Labs acquisition

INTERNATIONAL SALES - Significant increase in international revenue, up 208% yr/yr

U.S. EXPANSION - Began generating U.S. revenue and expanded distribution into new states

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
C$70.79 mln
C$68 mln (4 Analysts)
Q3 Gross Revenue
C$110.20 mln
Q3 Net Income
-C$6.29 mln
Q3 Adjusted EBITDA
C$5.69 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Organigram Global Inc is C$2.75, about 19.3% above its August 12 closing price of C$2.22

Press Release: ID:nBw4RhhwTa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)